TickerFacts.

CRISPR Therapeutics AG (CRSP): Revenue

Annual figures by period end, from SEC filings.

$3.51M
Year ended 2025-12-31
$13.39M
Trailing 12 months to 2026-06-30
+43.1%
3-year compound annual growth
+37.3%
5-year compound annual growth
+30.4%
10-year compound annual growth
$914.96M2015-12-31: $247.0K2016-12-31: $5.16M2017-12-31: $41.00M2018-12-31: $3.12M2019-12-31: $289.59M2020-12-31: $719.0K2021-12-31: $914.96M2022-12-31: $1.20M2023-12-31: $371.21M2024-12-31: $37.31M2025-12-31: $3.51M$3.51M
2015-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$3.51M-90.6%2026-02-12, From 2025-01-01
2024-12-31$37.31M-89.9%2026-02-12, From 2024-01-01
2023-12-31$371.21Mn/m2026-02-12, From 2023-01-01
2022-12-31$1.20M-99.9%2025-02-11, From 2022-01-01
2021-12-31$914.96Mn/m2024-02-21, From 2021-01-01
2020-12-31$719.0K-99.8%2023-02-21, From 2020-01-01
2019-12-31$289.59Mn/m2022-02-15, From 2019-01-01
2018-12-31$3.12M-92.4%2021-02-16, From 2018-01-01
2017-12-31$41.00M+693.9%2020-02-12, From 2017-01-01
2016-12-31$5.16Mn/m2019-02-25, From 2016-01-01
2015-12-31$247.0Kn/a2018-03-08, From 2015-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
CRISPR Therapeutics AG (CRSP)2025-12-31$3.51M-90.6%
Surrozen, Inc. (SRZN)2025-12-31$3.48M-67.4%
Dyadic International Inc (DYAI)2025-12-31$3.09M-11.6%
CG Oncology, Inc. (CGON)2025-12-31$4.04M+254.7%
Ocugen, Inc. (OCGN)2025-12-31$4.41M+8.8%
Prime Medicine, Inc. (PRME)2025-12-31$4.63M+55.3%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$5.20M+12.5%
Aligos Therapeutics, Inc. (ALGS)2025-12-31$2.19M-39.5%
DBV Technologies S.A. (DBVT)2025-12-31$5.64M+35.8%

Compare CRSP, SRZN, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗